European Journal of Heart Failure最新文献

{"title":"Integrated role of cardiac magnetic resonance and genetics in predicting left ventricular reverse remodelling in dilated and non-dilated cardiomyopathy.","authors":"Martina Setti,Manuela Iseppi,Job A J Verdonschot,Jacopo G Rizzi,Alessia Paldino,Carola Pio Loco Detto Gava,Giulia Barbati,Matteo Dal Ferro,Max F G H M Venner,Anne G Raafs,Marta Gigli,Davide Stolfo,Antonio De Luca,Giulia De Angelis,Teresa M Capovilla,Sharon Graw,Flavio L Ribichini,Matthew Taylor,Luisa Mestroni,Stephane R B Heymans,Gianfranco Sinagra,Marco Merlo","doi":"10.1002/ejhf.3671","DOIUrl":"https://doi.org/10.1002/ejhf.3671","url":null,"abstract":"AIMSLeft ventricular reverse remodelling (LVRR) is a prognostic marker in patients with dilated (DCM) and non-dilated left ventricular cardiomyopathy (NDLVC). The utility of combining late gadolinium enhancement (LGE) and genetic testing in predicting LVRR in DCM/NDLVC remains a knowledge gap. This study aimed to assess an integrated approach including LGE data and genetics to predict LVRR in DCM/NDLVC patients.METHODS AND RESULTSThis multicentre observational study included DCM/NDLVC patients with: (i) baseline echocardiographic left ventricular ejection fraction (LVEF) <50%; (ii) genetic testing; (iii) baseline cardiac magnetic resonance (CMR); (iv) 12-month follow-up echocardiographic data. LVRR was defined as LVEF increase ≥10% or LVEF ≥50% (if baseline LVEF <45%) at 12 months. Outcome measures were: (i) all-cause mortality, heart transplant, or left ventricular assist device implantation (D/HT/LVAD); (ii) sudden cardiac death or major ventricular arrhythmias (SCD/MVA). Arrhythmogenic genes studied were LMNA, DSP, FLNC, and RBM20. Among 1757 DCM/NDLVC with genetic data, 616 met eligibility (462 DCM, 154 NDLVC; age 51 ± 14 years, 34% female). LVRR occurred in 314 patients (51%): 251 (54%) in DCM and 63 (41%) in NDLVC (p = 0.004). Independent predictors of LVRR within 1 year included titin truncating variants, absence of arrhythmogenic genes, and absence of LGE ring-like pattern. In patients with LVEF <35%, only the presence of LGE ring-like pattern and arrhythmogenic genes remained independently related to a lower rate of LVRR and increased SCD/MVA risk.CONCLUSIONIn a large genetically and CMR characterized DCM/NDLVC cohort, arrhythmogenic genotypes and LGE ring-like pattern were inversely related to LVRR, particularly in patients with LVEF <35%.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"15 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials","authors":"Stefan D. Anker, Tim Friede, Javed Butler, Khawaja M. Talha, Marius Placzek, Monika Diek, Anna Nosko, Adriane Stas, Stefan Kluge, Dominik Jarczak, Geraldine Deheer, Meike Rybczynski, Antoni Bayes-Genis, Frank Edelmann, Gerasimos Filippatos, Gerd Hasenfuß, Wilhelm Haverkamp, Mitja Lainscak, Ulf Landmesser, Iain C. Macdougall, Bela Merkely, Burkert M. Pieske, Fausto J. Pinto, Tienush Rassaf, Maurizio Volterrani, Stephan von Haehling, Markus S. Anker, Wolfram Doehner, Hüseyin Ince, Friedrich Koehler, Gianluigi Savarese, Ursula Rauch-Kröhnert, Tommaso Gori, Teresa Trenkwalder, Ibrahim Akin, Christina Paitazoglou, Iwona Kobielusz-Gembala, Witold Zmuda, Luca Kuthi, Norbert Frey, Manuela Licka, Stefan Kääb, Karl-Ludwig Laugwitz, Piotr Ponikowski, Mahir Karakas","doi":"10.1002/ejhf.3658","DOIUrl":"https://doi.org/10.1002/ejhf.3658","url":null,"abstract":"Prior randomized trials have reported conflicting evidence regarding the efficacy of intravenous (IV) iron in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency (ID).","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"93 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF","authors":"Toru Kondo, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Meike Brinker, James Lay-Flurrie, Patrick Schloemer, Prabhakar Viswanathan, Flaviana Amarante, Chern-En Chiang, Gerasimos Filippatos, Carolyn S.P. Lam, Mark C. Petrie, Michele Senni, Morten Schou, Subodh Verma, Adriaan A. Voors, Dirk von Lewinski, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V McMurray","doi":"10.1002/ejhf.3669","DOIUrl":"https://doi.org/10.1002/ejhf.3669","url":null,"abstract":"FINEARTS-HF demonstrated the efficacy of finerenone in reducing total worsening heart failure (HF) events (first and recurrent) and cardiovascular death, compared to placebo, in patients with HF and mildly reduced or preserved ejection fraction. We examined the effect of finerenone on these events according to their clinical importance using win statistics.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"19 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What's new in heart failure? April 2025","authors":"Alberto Aimo,&nbsp;Pau Codina,&nbsp;Matthew M.Y. Lee,&nbsp;Daniela Tomasoni,&nbsp;Michael Böhm","doi":"10.1002/ejhf.3662","DOIUrl":"https://doi.org/10.1002/ejhf.3662","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"27 4","pages":"611-613"},"PeriodicalIF":16.9,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143880025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC","authors":"Antoni Bayes‐Genis, Matteo Pagnesi, Pau Codina, William T. Abraham, Offer Amir, Rudolf A. de Boer, Jasper J. Brugts, Ovidiu Chioncel, Finn Gustafsson, JoAnn Lindenfeld, Wilfried Mullens, Mark C. Petrie, Giuseppe Rosano, Marco Metra","doi":"10.1002/ejhf.3619","DOIUrl":"https://doi.org/10.1002/ejhf.3619","url":null,"abstract":"Episodes of worsening heart failure (HF) are a major cause of unplanned hospitalizations. Their onset is usually preceded by an early increase in intracardiac pressures with subsequent worsening of symptoms due to congestion. Implantable devices allowing daily remote pulmonary artery pressure (PAP) monitoring are useful to identify early haemodynamic changes so that medical therapy can be adjusted at an early stage, before symptom onset, and HF‐related hospitalizations be prevented. Second, the use of these devices may help to maintain clinical stability keeping PAP in the target range on a day‐to‐day basis. The CardioMEMS system allows remote PAP monitoring, and PAP‐guided medical therapy has reduced HF‐related hospitalizations in prospective, randomized, controlled clinical trials in symptomatic patients with HF, independent of their left ventricular ejection fraction. The safety and feasibility of other devices, like the Cordella implantable PAP sensor, have also been demonstrated and clinical usefulness in larger patient populations is currently being assessed in several trials. Most of the studies testing remote PAP monitoring were reported after the 2021 European Society of Cardiology HF guidelines. An update of the clinical significance and potential implications for clinical practice of these systems seems therefore warranted. The aim of this clinical consensus statement is to summarize current knowledge on remote PAP‐guided management of patients with HF, with a special focus on current evidence from clinical trials, potential impact on clinical practice and management aspects.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"9 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143880307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart failure in patients with a systemic right ventricle: A multicentre study with long-term follow-up","authors":"Mohammad Mostafa Ansari Ramandi, Werner Budts, Jolien W. Roos-Hesselink, Willem A. Helbing, Anastasia D. Egorova, Berto J. Bouma, Anthonie Duijnhouwer, Roland van Kimmenade, Gertjan T. Sieswerda, Thelma C. Konings, Lodewijk J. Wagenaar, Joey F.A. Ubachs, Rolf M.F. Berger, Elke S. Hoendermis, Adriaan A. Voors, Joost P. van Melle","doi":"10.1002/ejhf.3664","DOIUrl":"https://doi.org/10.1002/ejhf.3664","url":null,"abstract":"Adult patients with transposition of the great arteries (TGA) and an systemic right ventricle (sRV) are at risk for heart failure (HF). In this study, we investigated risk factors for HF hospitalization and developed a novel risk stratification tool to optimize risk prediction for clinical practice.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"1 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)","authors":"Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, Antoni Bayes-Genis, Ovidiu Chioncel, James Fang, Barry Greenberg, Nasrien E. Ibrahim, Teruhiko Imamura, Takayuki Inomata, Koichiro Kuwahara, Brenda Moura, Anekwe Onwuanyi, Naoki Sato, Gianluigi Savarese, Yasuhiko Sakata, Nancy Sweitzer, Jane Wilcox, Kazuhiro Yamamoto, Marco Metra, Andrew J.S. Coats","doi":"10.1002/ejhf.3646","DOIUrl":"https://doi.org/10.1002/ejhf.3646","url":null,"abstract":"This clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice. Heart failure is traditionally classified on the basis of LVEF thresholds and this has major implications for treatment recommendations. However, the reproducibility of LVEF measurement is poor and its prognostic and diagnostic value lessens when it is above 45%, with no relationship with the severity of either cardiac dysfunction or outcomes at higher values. These limitations dictate the need for a more comprehensive approach to classify and assess heart failure focusing more on the trajectory of LVEF rather than to its absolute value. Furthermore, the assessment of LVEF is not required for the initiation of treatments like sodium–glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists and diuretics in patients with suspected de novo heart failure and elevated N-terminal pro-B-type natriuretic peptide levels. Future research utilizing advanced imaging techniques and biomarkers which can better characterize myocardial structure, metabolism and performance may facilitate the identification of alternative therapeutic targets and better ways to monitor heart failure therapies across the entire spectrum of LVEF.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"25 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-related penetrance of phospholamban p.Arg14del cardiomyopathy.","authors":"Tom E Verstraelen,Freyja H M van Lint,Remco de Brouwer,Virginnio M Proost,Esmee van Drie,Laurens P Bosman,Lotte Weverink,Karim Taha,Thais Bueren,Aeilko H Zwinderman,Cathelijne Dickhoff,Toon Oomen,Bas A Schoonderwoerd,Tjeerd Germans,Arjan C Houweling,Juan R Gimeno-Blanes,Folkert W Asselbergs,Paul A van der Zwaag,Anneline S J M Te Riele,Rudolf A de Boer,Maarten P van den Berg,J Peter van Tintelen,Arthur A M Wilde","doi":"10.1002/ejhf.3672","DOIUrl":"https://doi.org/10.1002/ejhf.3672","url":null,"abstract":"AIMSPrevious studies have shown that carriers of the pathogenic p.Arg14del variant in phospholamban (PLN) have an increased risk of mortality, heart failure and malignant ventricular arrhythmias. However, there are sparse data on the penetrance of cardiac features in these mutation carriers, and the optimal starting age and intervals of clinical follow-up remain to be defined.METHODS AND RESULTSWe collected clinical data from PLN p.(Arg14del) carriers. Cardiac penetrance was defined as the presence of a major event or risk factor. A major event consisted of malignant ventricular arrhythmias or symptomatic heart failure. Risk factors were low-voltage electrocardiogram, repolarization abnormalities, frequent premature complexes, left ventricular ejection fraction <45% or cardiac fibrosis on magnetic resonance imaging. Kaplan-Meier analysis with and without left truncation was used to assess penetrance. We identified 868 p.(Arg14del) carriers, with a median age of 43 (interquartile range [IQR] 29-55) years at first cardiac evaluation. Median follow-up was 5.3 (IQR 2.2-8.5) years and 207 (23.8%) carriers had a major event, at a mean age of 51 (± 15) years. Penetrance was age-related, with new cardiac phenotypes emerging from adolescence to senior age. At age 70, penetrance of a major event was 43% to 70%, penetrance of a risk factor was 84% to 100% depending on which Kaplan-Meier method was used.CONCLUSIONPenetrance of a major cardiac event is high in PLN p.(Arg14del) carriers, with a penetrance up to 70% at age 70. Penetrance of a cardiac risk factor is nearly complete at older age. Furthermore, cardiac phenotypes can emerge from adolescence to senior age. Life-long cardiac follow-up is needed, starting from adolescence.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"69 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143866384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weight","authors":"Jawad H. Butt, Scott D. Solomon, Muthiah Vaduganathan, Dirk J. van Veldhuisen, Lars Køber, Bertram Pitt, Faiez Zannad, Pardeep S. Jhund, John J.V McMurray","doi":"10.1002/ejhf.3665","DOIUrl":"https://doi.org/10.1002/ejhf.3665","url":null,"abstract":"Obesity is associated with excessive adipocyte-derived aldosterone secretion, independent of the classical renin–angiotensin–aldosterone cascade, and mineralocorticoid receptor antagonists (MRAs) may be more effective in obese patients with heart failure (HF) with reduced ejection fraction (HFrEF).","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"29 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial","authors":"Sebastiaan Dhont, Philippe B. Bertrand, Jonas Erzeel, Sébastien Deferm, Laurent Pison, Pieter M. Vandervoort, Wilfried Mullens, W.H. Wilson Tang, Pieter Martens","doi":"10.1002/ejhf.3668","DOIUrl":"https://doi.org/10.1002/ejhf.3668","url":null,"abstract":"Atrial fibrillation (AF) and mitral regurgitation (MR) frequently coexist. While catheter ablation is a key rhythm-control strategy in AF, its impact on MR severity remains uncertain. This study evaluates the effects of catheter ablation on AF recurrence, functional status, and MR progression in patients with AF and baseline MR.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"67 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}